ITRMF · Iterum Therapeutics plc
$0.03
+0.00 (+0.00%)
At close · Jul 23
Going-concern doubt
— flagged Nov 14, 2025
Substantial doubt about the company's ability to continue as a going concern.
“We have identified conditions and events that raise substantial doubt about our ability to continue as a going concern.”View the 10-Q filed Nov 14, 2025
Market Cap
$1.38M
Shares
44.66M
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$0.03
Open$0.03
Day$0.03–0.03
52W$0.01–0.91
Avg vol 30d38K
Short int1.2M · 2.7% float · 21.5d
Short vol52%
Last earningsNov 14, 2025
DataJan 2020–Jul 2026
Filing10-Q · Nov 14
Up next
FQ3-26 quarter ends
~Sep 30, 2026
Est
filed Nov 14, 2025
Equibles Rating
blended score · not investment adviceOverall
Sell
SellHoldBuy
Technical
Strong Sell
Momentum
Very Weak
Sentiment
Neutral
Fundamentals
Strong
Quant / Vol
Very High
Market backdrop
VIX 18.6 · elevated
Equity put/call 0.79
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
−88%
below
Price vs 50-day avg
−32%
below
RSI (14)
45
neutral
MACD trend
Negative
52-week position
3%
near low
Volume (OBV)
Confirms
volume backs price
Momentum
relative strength
1-month return
−34%
trailing
6-month return
−90%
trailing
YTD return
−91%
this year
Relative strength
−96%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $0 › 200d $0 — 200d above 50d
Institutional flow
Accumulating
+13% holders QoQ · +10 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
2.68% of float · ▲ +17.4% MoM · 21.5 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
18 holders — mid 3-yr range
Squeeze score
47
elevated · 0–100
Fundamentals
EPS growth
+57%
Y/Y
Free cash flow
$-26.8M
Balance sheet
$11.0M
net cash
Quant / Vol
risk profile
Volatility
388%
annualized · 1-yr
Max drawdown
−99%
past year
ATR
38.1%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders Strong Sell
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
−88%
Bearish
Price vs 50-day avg
−32%
Bearish
RSI (14)
45
Neutral
MACD trend
Negative
Bearish
52-week position
3%
Bearish
Volume (OBV)
Confirms
Neutral
Market signals — smart money & positioning
Mixed
Trend (MA cross)
No cross
50d $0 › 200d $0 — 200d above 50d
Institutional flow
Accumulating
+13% holders QoQ · +10 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
2.68% of float · ▲ +17.4% MoM · 21.5 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
18 holders — mid 3-yr range
Price context
position in its 52-week range
52-wk low $0
Now $0 · 3%
52-wk high $1
vs 200-day avg -88%
vs 50-day avg -32%
Illustrative technical + ownership context — a signal mix, not investment advice.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
ITRMF
this stock
Iterum Therapeutics plc
|
$1.38M | -90.7% | -95.7% | — | 2.7% |
|
ONC
BeOne Medicines Ltd.
|
$471.01B | +7.6% | +22179.2% | 958.5 | 0.1% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$121.16B | +4.4% | +46.2% | 28.3 | 2.0% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$68.78B | -15.4% | +20.8% | 16.0 | 3.3% |
|
ARGX
Argenx SE
|
$57.44B | +9.9% | — | — | 2.5% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Institutional Holders
Reducing
Holders
18
- % held
- 3.2%
- Net QoQ
- -30.8K sh
- Top holder
- HRT FINANCIAL LP
Held
Float
Short & Settlement
Financials
Filings
Earnings & Events
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| ITRMF | +14.8% | -34.0% | -90.1% | -38.0% | -90.8% |
| SPY | -1.7% | +0.7% | +6.4% | -1.2% | +8.3% |
| vs SPY | +16.5% | -34.7% | -96.5% | -36.9% | -99.0% |